Skip to main content
. 2023 Sep 14;15(1):59–69. doi: 10.1136/flgastro-2023-102400

Figure 2.

Figure 2

Managing potential adverse events of JAK inhibition. ALC, absolute lymphocyte count; ANC, absolute neutrophil count; CVS, cardiovascular; CVD, cerebrovascular disease; ESRF, end-stage renal failure; IHD, ischaemic heart disease; JAK, Janus kinase; LFTs, liver function tests; MACE, major adverse cardiovascular events; NMSC, non-melanoma skin cancer; VTE, venous thromboembolism.

HHS Vulnerability Disclosure